The Chinese non-small-cell lung cancer (NSCLC) drug market is expected to more than double by 2013

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.579, 2009-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

BMS 184476 shows "remarkable activity" in patients with previously-treated non-small-cell lung cancer (NSCLC)

Inpharma, Vol. 1, Iss. 1486, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

The combination of irinotecan plus carboplatin has antitumour activity in non-small-cell lung cancer (NSCLC)

Inpharma, Vol. 1, Iss. 1473, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC)

By Blumenschein George

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1802-1811

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to “Work it Out”?

Current Pharmaceutical Design, Vol. 20, Iss. 24, 2014-01 ,pp. : 3863-3874

Bentham Science Publishers

Access to resources Recommend Favorite